Loading stock data…
$6.29-0.48 (-7.09%)
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers.
Artiva Biotherapeutics, Inc. in the Healthcare sector is trading at $6.29 with a market capitalization of $547M. Wall Street consensus targets $35.80 (5 analysts), implying a +469.2% move over the next 12 months. The stock is currently 57% below its 52-week high of $14.53, remaining 21.0% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 26 is oversold, raising the odds of a near-term bounce. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$26.89M↓ | -$24.43M↓ | -$21.93M↑ | -$22.90M↓ | -$22.81M |
| Net Income | -$25.00M↓ | -$23.52M↓ | -$20.77M↑ | -$21.53M↓ | -$21.25M |
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-s...